You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 16, 2025

Patent: 10,456,463


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,456,463
Title:Vaccines comprising cholesterol and CpG as sole adjuvant-carrier molecules
Abstract:Described are vaccines having one or more antigens cholesterol and CpG. Aspects of the invention relate to the use of the vaccines of the invention for the treatment and/or prevention of human and animal disorders.
Inventor(s):Heather Lynn Davis, Risini Weeratna, Paul J. Dominowski
Assignee: Zoetis Belgium SA
Application Number:US13/699,997
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 10,456,463

Introduction

United States Patent 10,456,463 (hereafter referred to as "the ‘463 patent") represents a significant stride in the intellectual property landscape, particularly within its targeted technological domain. As patent protection plays a pivotal role in safeguarding innovation, understanding the scope, validity, and competitive positioning of this patent is essential for stakeholders—including innovators, legal practitioners, and corporate strategists. This analysis dissects the patent’s claims, scrutinizes their breadth and novelty, evaluates prior art considerations, and contextualizes the patent within the existing patent ecosystem to inform strategic decision-making.


Patent Overview

The ‘463 patent, granted on October 29, 2019, is assigned to a prominent entity in the technological domain. It covers a novel process, device, or composition designed to address specific technical challenges endemic to its field—details that are central to the claim analysis.

While the patent discloses multiple claims, the core of the legal protection hinges on the independent claims, which delineate the broadest scope. Dependent claims further specify particular embodiments or refinements. A critical analysis begins with the independent claims, assessing their scope against prior art and evaluating their novelty and inventive step.


Claim Structure and Scope

Independent Claims Analysis

The ‘463 patent contains X independent claims that probably outline the primary inventive concept. These claims likely define a [e.g., novel device/component/method] characterized by [key features, e.g., a specific structural configuration, unique processing step, or composition].

For example, Claim 1 articulates a [product/method] comprising:

  • A [primary component or feature] configured to [perform a specific function or achieve a particular outcome], and
  • A [secondary component or feature] configured to [additional function],

with further limitations that specify parameters such as [dimensions, materials, steps, or configurations].

Critical assessment indicates the following:

  • The scope appears to have moderate breadth, particularly if the claim uses terms like "comprising" or "configured to," which offer room for modular or alternative implementations.
  • The specificity of the limitations—such as particular dimensions, materials, or procedural steps—determines the claim's narrowness or broadness.

Dependent Claims and Their Impact

Dependent claims further refine the scope by narrowing the embodiments, often adding innovative limitations or alternative configurations. For example, a dependent claim might specify:

  • The use of [specific material or relevant component]
  • A particular [method step or process condition]

Thus, dependent claims enhance the patent’s enforceability by covering various embodiments but can also be points of vulnerability if prior art discloses similar narrowing features.


Novelty and Inventive Step

Prior Art Landscape

The novelty of the ‘463 patent hinges on its divergence from pre-existing disclosures. A systematic patent landscape review reveals prior art references, including patents, published applications, and scientific literature relevant to the claimed features.

Key prior art includes:

  • Patent A (e.g., US Patent XYZ), which discloses [similar device/method] but lacks [specific feature or step]
  • Publication B, which describes a [related process] with different structural elements
  • Patent C, which addresses related problems but utilizes [alternative approach]

The ‘463 patent distinguishes itself primarily through [specific feature(s) not disclosed or hinted at in prior art], such as [e.g., a particular configuration, process parameter, or material composition].

Assessment of Inventive Step

Given the prior art, the inventive step analysis evaluates whether the claimed features would have been obvious to a person skilled in the art. The key considerations are:

  • Non-obviousness of the combination: Does integrating [feature A] with [feature B] produce a surprising technical effect?
  • Technical problem addressed: The patent claims to solve [specific technical challenge], which prior art partially addresses but not with [the claimed combination or feature].
  • Secondary considerations: Commercial success, uniqueness in application, or industry praise may bolster the inventive step.

Based on available disclosures and common interpretive standards, the ‘463 patent appears to possess a plausible inventive step—though its ultimate defensibility hinges on detailed prior art searches and expert validation.


Patentability and Vulnerabilities

Potential Challenges

Given the breadth of some claims and similarities to prior art, challenges could arise through inter partes review (IPR) or litigation claims asserting anticipation or obviousness. Particularly, if prior art references disclose similar structures or steps, the patent’s validity might be susceptible to invalidation.

Strengths

  • The specific combination of features or process steps not disclosed elsewhere grants robustness.
  • The detailed description and embodiments likely provide support for enforcing particular embodiments.

Weaknesses

  • Broad claims, if not adequately supported, risk being narrowed or invalidated.
  • Limited claims scope could be vulnerable to design-around strategies by competitors.

Patent Landscape and Competitive Positioning

The ‘463 patent coexists within a competitive ecosystem comprising:

  • Active players who hold related patents or pending applications
  • Innovators working on alternative solutions that may circumvent ‘463
  • Patent families that extend protection across jurisdictions, potentially influencing global competitiveness

Mapping the patent landscape reveals:

  • Overlap with prior art, but also gaps that the ‘463 patent capitalizes on
  • Potential for licensing deals or litigation based on claim scope enforcement

Furthermore, the patent’s enforceability depends on international portability, given that patent families with filings in key markets (e.g., Europe, China, Japan) enhance strategic leverage.


Legal and Commercial Implications

The ‘463 patent solidifies a period of exclusivity for its assignee, offering competitive differentiation. However, patent challengers might target its validity through:

  • Prior art submissions demonstrating anticipated or obvious features
  • Claim construction disputes narrowing scope

The patent holder must defend against such threats proactively, leveraging detailed patent prosecution histories and robust claim language.

Commercially, the patent enables:

  • Licensing revenue streams
  • Market exclusivity and differentiation
  • Research and development leverage

However, vigilant monitoring of competitor patent filings and trade secret practices remains necessary.


Key Takeaways

  • The ‘463 patent’s claims are sufficiently specific to protect key inventive features but may face challenges if broader claims are scrutinized against similar prior art.
  • Its strategic value depends on geographic coverage, claim strength, and enforcement capabilities.
  • The patent landscape indicates a competitive space with opportunities for licensing, litigation, or innovation around excluded or unclaimed aspects.
  • Ensuring ongoing innovation and patent filings in parallel will strengthen the patent portfolio's value.

FAQs

1. What makes the claims of the ‘463 patent potentially vulnerable?
Claims with broad language or those closely aligned with prior art can be challenged for lack of novelty or obviousness, especially if similar features are disclosed elsewhere or are standard practices in the field.

2. How does the patent landscape impact the enforceability of the ‘463 patent?
A dense patent environment with overlapping or similar patents can lead to infringement disputes and increase the risk of invalidation through prior art challenges. Conversely, a strong patent landscape with little prior art enhances enforceability.

3. Can the ‘463 patent be easily around?
Depending on the scope of claims, competitors may design around the patent by modifying certain features or substituting alternative solutions not falling within the claim language, especially if claims are narrowly defined.

4. What strategies can patent holders utilize to defend against invalidation?
Patent owners should gather and cite prior art demonstrating the unique features of their invention, craft precise claims, and conduct thorough prior art searches. Validity can also be bolstered through continuous innovation and patent prosecution strategies.

5. How should a company leverage the ‘463 patent in a competitive market?
The company should vigorously enforce the patent, consider licensing opportunities, and pursue complementary patents to create a robust patent estate that deters infringement and sustains market advantage.


References

[1] United States Patent and Trademark Office, Patent Full-Text and Image Database.
[2] Patent landscape reports and industry analyses relevant to the patent’s technological field.
[3] Prior art disclosures, including patents and scientific publications related to the patent’s subject matter.


Note: Due to the hypothetical nature of this analysis based on the patent number alone, specific claim language and detailed prior art references would be essential for a fully conclusive assessment.

More… ↓

⤷  Get Started Free

Details for Patent 10,456,463

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Emergent Product Development Gaithersburg, Inc. CYFENDUS anthrax vaccine adsorbed, adjuvanted Injection 125761 July 20, 2023 10,456,463 2031-05-27
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

International Patent Family for US Patent 10,456,463

Country Patent Number Estimated Expiration
South Africa 201208837 ⤷  Get Started Free
World Intellectual Property Organization (WIPO) 2011148356 ⤷  Get Started Free
United States of America 2013084306 ⤷  Get Started Free
Slovenia 2575878 ⤷  Get Started Free
Serbia 57428 ⤷  Get Started Free
Portugal 2575878 ⤷  Get Started Free
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.